Know Cancer

or
forgot password

A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib


Phase 2
21 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib


Inclusion Criteria:



- A history of stage I-IIIB NSCLC

- Previously underdone definitive surgery or radiation

- Received prior adjuvant treatment or neoadjuvant with erlotinib or gefitinib for a
total of at least 3 months at any time

- Stopped adjuvant erlotinib or neoadjuvant at least 2 months prior to date of first
imaging demonstrating recurrence

- Pathologic evidence of recurrent lung cancer, confirmed at MSKCC EGFR sensitizing
mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be
documented in the primary or recurrent tumor

- Tissue from their recurrent tumor must be submitted for EGFR mutation testing, and to
evaluate for the presence of the T790M mutation (results do not need to have been
reported to be eligible)

- Measurable disease by RECIST; if received prior irradiation, then must have a target
lesion outside the irradiated field

- Signed informed consent

- Age > or = to 21 years old

- Persons of reproductive potential must agree to use an adequate method of
contraception throughout treatment and for at least 4 weeks after study drug is
stopped

Exclusion Criteria:

- Prior progressive disease while receiving erlotinib or gefitinib therapy

- Patients with known pre-existing interstitial lung disease

- Total bilirubin greater than 1.8 mg/dl, excepting patients known to have Gilbert's
syndrome

- AST or ALT greater than five times the upper limit of normal

- Pregnant or lactating women

- Medically unfit for erlotinib therapy as determined by treating oncologist

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To examine the objective response rate (ORR) of single-agent erlotinib

Outcome Description:

in recurrent EGFR-mutant lung cancer, given to patients who previously received adjuvant erlotinib or gefitinib

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Christopher Azzoli, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

10-097

NCT ID:

NCT01189435

Start Date:

August 2010

Completion Date:

August 2012

Related Keywords:

  • Lung Cancer
  • OSI-774, TARCEVA (ERLOTINIB)
  • Lung
  • recurrent
  • 10-097
  • Gefitinib
  • Lung Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021